Crewe Advisors’s United Therapeutics UTHR Stock Holding History

Crewe Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-31	Closed	-$6.94K	–	1013
2023 Q1	$6.94K	Sell	31 -3	-9%	-$740	﹤0.01%	596
2022 Q4	$9.46K	Buy	34 +3	+10%	+$757	﹤0.01%	559
2022 Q3	$6K	Hold	31	–	–	﹤0.01%	825
2022 Q2	$7K	Buy	+31	New	+$6.3K	﹤0.01%	700

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Crewe Advisors's UTHR Position: Q2 2023 in Review

Crewe Advisors sold out of United Therapeutics (UTHR) in Q2 2023, closing a stake of 31 shares — an estimated $6.94K sold.

Crewe Advisors first reported a position in UTHR in Q2 2022 and held it in 4 quarters. The position peaked at $9.46K in Q4 2022. 473 funds tracked by Wall St. Rank hold UTHR as of Q2 2023.

Crewe Advisors reported no remaining United Therapeutics position as of Q2 2023 after selling out during the quarter.
Crewe Advisors sold 31 United Therapeutics shares in Q2 2023, an estimated $6.94K.
Crewe Advisors first reported a position in United Therapeutics in Q2 2022 and held it in 4 quarters.
Crewe Advisors's United Therapeutics position peaked at $9.46K in Q4 2022.
473 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2023.

Based on Crewe Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.